Approval Package for:

APPLICATION NUMBER:

212887Orig1s000
212888Orig1s000

Trade Name: Vocabria 30 mg tablet
Cabenuva extended release injectable suspension

Generic or Proper Name: Cabotegravir
Cabotegravir/rilpivirine

Sponsor: ViiV Healthcare Company

Approval Date: January 21, 2021

Indication: For the use of Vocabria (cabotegravir) 30 mg tablet in combination with Edurant (rilpivirine) 25 mg tablet for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, for use as:

- oral lead-in to assess the tolerability of cabotegravir prior to administration of Cabenuva (cabotegravir extended release injectable suspension; rilpivirine) extended release injectable suspension)
- oral therapy for patients who will miss planned injection dosing with Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension)

For the use of Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension) as a complete regimen for the treatment of HIV-1 infection in adults to replace their current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td>X</td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Integrated Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

212887Orig1s000
212888Orig1s000

APPROVAL LETTER
Dear Dr. Austin:

Please refer to your new drug application (NDA) dated April 29, 2019, received April 29, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vocabria (cabotegravir) 30 mg tablet.

We acknowledge receipt of your amendment dated July 28, 2020, which constituted a complete response to our December 19, 2019, action letter.

This new drug application provides for the use of Vocabria (cabotegravir) 30 mg tablet in combination with Edurant (rilpivirine) 25 mg tablet for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, for use as:

- oral lead-in to assess the tolerability of cabotegravir prior to administration of Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension)
- oral therapy for patients who will miss planned injection dosing with Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension)

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

Reference ID: 4734271
As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling \([21 \text{ CFR } 314.50(l)]\) in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.\(^1\) Content of labeling must be identical to the enclosed labeling (Prescribing Information and Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As.*\(^2\)

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on January 5, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications.* For administrative purposes, designate this submission *“Final Printed Carton and Container Labeling for approved NDA 212887.”* Approval of this submission by FDA is not required before the labeling is used.

**DATING PERIOD**

Based on the stability data provided, the expiration dating period for Vocabria (cabotegravir) tablet is 24 months when stored below 30 °C (86 °F).

**ADVISORY COMMITTEE**

Your application for Vocabria was not referred to an FDA advisory committee because the clinical trial design is acceptable and the application did not raise significant safety or efficacy issues that were unexpected in the intended population.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for}

---

2. We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study(ies) requirement for this application from birth to less than 2 years of age because necessary studies are impossible or highly impractical due to the success of interventions preventing mother to child transmission of HIV-1 infections and limited population available for recruitment in this age group.

We are deferring submission of your pediatric studies for ages 2 to less than 18 years of age and weighing at least 10 kg and higher for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act/FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act/FDCA. These required studies are listed below.

3997-1  Conduct a study in subjects weighing 35 kg and higher (approximately 12 to less than 18 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, tolerability, and short-term safety of VOCABRIA after 4-week administration in combination with other antiretroviral drug(s).

   Study Completion: 7/2022
   Final Report Submission: 1/2023

3997-2  Conduct a study in subjects weighing 25 kg to less than 35 kg (approximately 6 to less than 12 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, tolerability, and short-term safety of VOCABRIA after 4-week administration in combination with other antiretroviral drug(s).

   Final Protocol Submission: 8/2022
   Study Completion: 6/2023
   Final Report Submission: 12/2023

3997-3  Conduct a study in subjects weighing 10 kg to less than 25 kg (approximately 2 to less than 6 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, tolerability, and short-term safety of VOCABRIA after 4-week administration in combination with other antiretroviral drug(s).
pharmacokinetics, tolerability, and short-term safety of VOCABRIA after 4-week administration in combination with other antiretroviral drug(s).

Final Protocol Submission: 8/2022
Study Completion: 12/2025
Final Report Submission: 6/2026

FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.3

Submit the protocol(s) to your IND 109678 with a cross-reference letter to this NDA. Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.4

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.5 Information and Instructions for completing the form can be found at FDA.gov.6

3 See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).
4 For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
6 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Andrew Gentles, PharmD, BCPS AQ-ID, Senior Regulatory Project Manager, at (240) 402-5708 or the mainline at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

John Farley, MD, MPH
Director
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOHN J FARLEY
01/21/2021 02:48:21 PM
ViiV Healthcare Company
Attention: Beth Austin, PhD
Senior Director, Global Regulatory Affairs
5 Moore Drive, P.O., Box 13398
Research Triangle Park, NC 27709

Dear Dr. Austin:

Please refer to your new drug application (NDA) dated April 29, 2019, received April 29, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension).

We acknowledge receipt of your amendment dated July 28, 2020, which constituted a complete response to our December 19, 2019, action letter.

This new drug application provides for the use of Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension) as a complete regimen for the treatment of HIV-1 infection in adults to replace their current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

Reference ID: 4734300
Content of labeling must be identical to the enclosed labeling (Prescribing Information, Patient Package Insert and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on January 5, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission "Final Printed Carton and Container Labeling for approved NDA 212888." Approval of this submission by FDA is not required before the labeling is used.

**DATING PERIOD**

Based on the data provided, the expiration dating period for Cabenuva (cabotegravir extended release injectable suspension; rilpivirine extended release injectable suspension) is 24 months when stored at 2-8 °C (34-36 °F).

**ADVISORY COMMITTEE**

Your application for Cabenuva was not referred to an FDA advisory committee because the clinical trial design is acceptable and the application did not raise significant safety or efficacy issues that were unexpected in the intended population.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

---


2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

U.S. Food and Drug Administration
Silver Spring, MD 20993

[www.fda.gov](http://www.fda.gov)
We are waiving the pediatric study(ies) requirement for this application from birth to less than 2 years of age because necessary studies are impossible or highly impractical due to the success of interventions preventing mother to child transmission of HIV-1 infections and limited population available for recruitment in this age group.

We are deferring submission of your pediatric studies for ages 2 to less than 18 years of age and weighing at least 10 kg and higher for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act/FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act/FDCA. These required studies are listed below.

3998-1 Conduct a study in subjects weighing 35 kg and higher (approximately 12 to less than 18 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, safety and tolerability, and antiviral activity of CABENUVA. Study participants must be monitored for a minimum of 24 weeks to assess safety and durability of antiviral response.

Study Completion: 7/2022
Final Report Submission: 1/2023

3998-2 Conduct a study in subjects weighing 25 kg to less than 35 kg (approximately 6 to less than 12 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, safety and tolerability, and antiviral activity of CABENUVA. Study participants must be monitored for a minimum of 24 weeks to assess safety and durability of antiviral response.

Final Protocol Submission: 8/2022
Study Completion: 6/2023
Final Report Submission: 12/2023

3998-3 Conduct a study in subjects weighing 10 kg to less than 25 kg (approximately 2 to less than 6 years of age) who are HIV-1 infected, virologically suppressed (HIV-1 RNA <50 copies/mL) and on a stable antiretroviral regimen at the time of enrollment, to assess the pharmacokinetics, safety and tolerability, and antiviral activity of CABENUVA. Study participants must be monitored for a minimum of 24 weeks to assess safety and durability of antiviral response.
FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Submit the protocol(s) to your IND 109678 with a cross-reference letter to this NDA. Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies). When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.⁴

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁵ Information and Instructions for completing the form can be found at FDA.gov.⁶

³ See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).
⁴ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
⁶ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Andrew Gentles, PharmD, BCPS AQ-ID, Senior Regulatory Project Manager, at (240) 402-5708 or the mainline at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

John Farley, MD, MPH
Director
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Instructions for Use
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOHN J FARLEY
01/21/2021 02:57:30 PM